Last reviewed · How we verify
HyperAcute-Melanoma Vaccine
At a glance
| Generic name | HyperAcute-Melanoma Vaccine |
|---|---|
| Also known as | HAM-1, HAM-2, and HAM-3 |
| Sponsor | NewLink Genetics Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vaccine Treatment for Advanced Malignant Melanoma (PHASE1, PHASE2)
- A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HyperAcute-Melanoma Vaccine CI brief — competitive landscape report
- HyperAcute-Melanoma Vaccine updates RSS · CI watch RSS
- NewLink Genetics Corporation portfolio CI